A team-guided plan got most people with tricky lung cancer to curative care

If you or someone you love is facing lung cancer that doctors call hard to treat, here is encouraging news. A new study found that a team-guided plan helped nearly everyone reach treatment aimed at a cure.

The plan starts with medicine to shrink the tumor. Then a team of specialists meets and decides the best next step for each person. In this study, 92.3% of people ended up with either surgery or curative radiation. That includes people whose tumors were on the edge of being removable at the start.

How the study worked

This was a phase 2 study called MDT-BRIDGE. It followed 142 people with non-small cell lung cancer, the most common kind. About two-thirds had tumors doctors judged removable by surgery. The other third had “borderline” tumors, where it was not clear at first that surgery would work. Everyone first received durvalumab, an immunotherapy drug, plus chemotherapy. Then a team of surgeons, cancer doctors and radiation specialists looked at how each tumor responded and chose the next step. The results were published on Oct. 26, 2026, in Nature Medicine. All participants received the same plan with no comparison group, and survival results are still to come.

What they found

More than 7 in 10 people, 74.6%, had their tumor removed with surgery. That included many of the people with borderline tumors.

When surgeons operated, they got all of the visible tumor with clean edges in 96.2% of cases. That is the outcome surgeons hope for.

Some people were not good candidates for surgery after the first medicines. For them, the team switched to radiation combined with chemotherapy, which is also meant to cure. Put together, 92.3% of people, 131 of the 142, received either surgery (106 people) or this radiation treatment (25 people).

Most kept going with durvalumab afterward. In all, 82.4% received it after surgery or radiation.

Serious side effects during that later phase were not common. They happened in 7.4% of people who had surgery and 17.4% of those who had radiation. Some people stopped the medicine because of side effects: 8.5% of the surgery group and 13.0% of the radiation group. The researchers described these effects as manageable and in line with earlier studies.

Why a team makes a difference

A tumor can look one way on the first scans and another after a few weeks of treatment. Instead of locking in one plan on day one, this approach lets the team check how the tumor responds, then pick surgery or radiation. Each person gets the route that fits their own tumor.

Doctors often call this group a multidisciplinary tumor board. Many cancer centers in the US hold these meetings regularly.

What you can do today

If you or someone close to you has lung cancer, write down this question for the next visit: “Will my case be reviewed by a tumor board, a team of different specialists?” It is a simple question, and doctors hear it often.